BRCA1 and ovarian cancer: Quinn et al. showed that downregulation of BRCA1 by RNAi increased sensitivity to cisplatin in ovarian cancer cell lines (44), thus providing a rationale for the use of pharmacological agents in order to inhibit BRCA function.